Despite their great potential, these technologies face key challenges, particularly in data integration and clinical translation, highlighting the need for standardized methods, longitudinal sampling, and validation in relevant models to effectively exploit single-cell multi-omics and identify therapeutic vulnerabilities in the NRF2–NOTCH axis in lung cancer. This evidence concerns the gene NFE2L2 and lung carcinoma.